###### Key messages

Frequency of self-monitoring of blood glucose not found to affect A1C in non-insulin-dependent diabetes.Frequency of submission of online reports of blood glucose found to be correlated with A1C and frequency of self-monitoring of blood glucose.For patients who tested frequently, a difference in A1C was found between reporting frequently and infrequently, where no difference was found in those who tested infrequently.

The day-to-day management of diabetes mellitus is a complex and consistent challenge for patients and healthcare providers alike. Established patient self-management tools, such as self-monitoring of blood glucose (SMBG), are now being used in tandem with information technology and telecommunications to provide a more integrated management of the disease.

The benefits of intensive glycemic control have long been established both in type 1 and type 2 diabetes, and include reduced rates of microvascular complications,[@R1] [@R2] with SMBG providing the means to monitor progress and avoid hypoglycemia.[@R3] Although SMBG is well supported for frequent use in insulin-dependent diabetes,[@R4] there is controversy over self-testing in non-insulin-dependent type 2 diabetes and a lack of research on the importance of testing frequency on clinical outcomes.[@R9]

One line of reasoning as to why SMBG cannot consistently be shown to demonstrate an effect in non-insulin-dependent diabetes lies in the variability of decision-making as a result of SMBG.[@R10] With the advent of online communications, the Internet-based Blood Glucose Monitoring System (IBGMS) is a technology that is used to augment SMBG by giving patients the means to communicate their blood glucose levels to their healthcare provider for actionable feedback. This technology has been shown to reduce A1C in several randomized controlled trials for type 1 and type 2 diabetes.[@R11]

The purpose of this study was to evaluate the relationship between A1C, frequency of SMBG, and frequency of IBGMS reporting for patients with type 2 diabetes solely on oral medications.

Research design and methods {#s1}
===========================

IBGMS procedure {#s1a}
---------------

Patients recommended for IBGMS by their healthcare provider met with a research coordinator immediately following their clinical appointment for training on submitting reports. Patients were instructed to test their blood glucose before each meal and to report back every 2 weeks. Standardized reports providing the mean, SD, and range of daily glucose values were sent to a healthcare provider through a variety of methods, reflecting the individual patient\'s own comfort with technology. Patients reported online through meter software, a spreadsheet, or a simple online platform that allowed a healthcare provider to review each report and provide brief (typically 2--4 sentences) feedback to the patient. Necessary adjustments to each patient\'s oral medications were communicated, and positive reinforcement was provided if no changes were needed. It is important to note that IBGMS reporting operated in parallel with the conventional standard of diabetes care; although IBGMS patients have been shown to visit their endocrinologists less frequently,[@R14] they were offered the same short-term and yearly follow-up appointments as non-IBGMS patients.

Data collection {#s1b}
---------------

Chart data from 229 patients with type 2 diabetes registered for IBGMS within the past 3 years were evaluated. To be considered for the study, patients must have been taking oral agents alone for their type 2 diabetes, with a minimum of one IBGMS report submitted. A total of 191 patients fit the criteria and were used in the final analyses, while the remaining 38 had not submitted a report or were not treated solely on oral agents. Age and weight were collected as confounding variables to be controlled for, while frequency of SMBG and frequency of IBGMS reporting were used as the explanatory variables. SMBG frequency was defined as the average number of tests taken per day, calculated for each patient on the basis of their most recent report sent in to the healthcare provider. The reporting frequency was defined as the average number of reports per 3 months over the most recent 6-month period. A1C was collected and averaged over the same 6-month period for each patient and used as the response variable. Duration of diabetes, presence of diabetes complications (cataracts, retinopathy, nephropathy, neuropathy, arteriosclerotic heart disease, peripheral vascular disease or stroke), and the oral medication regimen of each patient during the study period were recorded for further insight into the patient subgroups.

Statistical methods {#s1c}
-------------------

Simple and multiple regression analyses were performed using the statistical software R to determine correlation coefficients and significance values. One-way analysis of variance tests were used to assess a relationship between diabetes complications and testing and reporting frequency. Welch\'s two sample t test was used for analyzing the baseline characteristics due to the higher total sample number. Wilcoxon rank-sum tests were used to determine statistically significant differences in the subgroup analysis; Pearson\'s χ^2^ test was used to test for significant differences in diabetes complications and medication regimes.

Results {#s2}
=======

A multiple regression analysis using age, weight, frequency of testing, and frequency of reporting as parameters showed that frequency of reporting had an inverse correlation to A1C (p\<0.05), whereas frequency of SMBG, age, and weight did not show statistical significance (p=0.158, p=0.068, p=0.195). A simple regression using only frequency of reporting similarly shows an inverse correlation with A1C (p\<0.05), as shown in [figure 1](#BMJDRC2015000134F1){ref-type="fig"}A. No relationship was observed between the number of diabetes complications present for each patient and their testing or reporting frequency (p=0.526 and p=0.642).

![Linear regression demonstrating (A) a trend of reduced A1C with higher reporting frequency and (B) a trend of increased reporting frequency with testing frequency.](bmjdrc2015000134f01){#BMJDRC2015000134F1}

To examine the effect that frequency of reporting had on frequency of SMBG, a simple regression analysis was performed using frequency of reporting as the dependent variable against frequency of testing. As seen in [figure 1](#BMJDRC2015000134F1){ref-type="fig"}B, it was found that there was a positive correlation between the two (p\<0.01).

Since frequency of reporting and SMBG were shown to be correlated, we examined further as to whether frequency of reporting and SMBG together produced an interactive effect on A1C, treating the two predictors as continuous variables. No statistically significant interaction was observed (data not shown). Subsequently, the data set was divided into infrequent and frequent testers as defined by those who tested their blood sugars on average once or less per day or twice or more per day. The sub-categorization of infrequent and frequent testers was empirically determined from clinical observations of the most common patient preferences toward daily testing. Patients testing an intermediate number of times between the two groups were rounded up or down accordingly.

Within those two groups, the data were further divided into infrequent and frequent reporters, as defined by those who report once or fewer times every 3 months, or more than once every 3 months. The interval of one report per 3 months was selected to simulate the frequency of follow-ups an endocrinologist might have with a patient, but all reporters in both groups were virtually receiving more contact with their endocrinologist than typically provided. To best manage both the unequal distributions and large difference in sample size ultimately present between the two subgroups, the Wilcoxon rank-sum test was used to test for significant differences in A1C.

[Table 1](#BMJDRC2015000134TB1){ref-type="table"} summarizes the baseline characteristics of the infrequent and frequent testing groups, with no significant differences in age, weight, duration of diabetes or A1C. An overview of the oral medications taken by both groups during the study period is also provided; there was only a significant difference observed between groups in the proportion of patients taking Metformin solely for their diabetes management (p=0.033). There was no significant difference in the presence of diabetes complications between the two groups (p=0.081), with 132 of 191 patients experiencing at least one complication overall.

###### 

Baseline characteristics and oral medication regimens among the infrequent and frequent testing groups

                                       Infrequent testers   Frequent testers   p Value
  ------------------------------------ -------------------- ------------------ ---------
  N                                    73                   118                
  Age                                  63±12                65±11              0.062
  Gender (male)                        40 (54.7%)           57 (48.3%)         0.383
  Weight (kg)                          89.5±24.3            82.7±23.6          0.347
  Duration of diabetes                 15±7                 16±9               0.325
  A1C (%, mmol/mol)                    7.3±0.9 (56±10)      7.5±1.0 (58±69)    0.123
  Diabetes complications               45 (61.6%)           87 (73.7%)         0.081
  Metformin only                       19 (26.0%)           16 (13.6%)         0.033\*
  Metformin+Sulfonylurea               18 (24.7%)           24 (20.3%)         0.486
  Metformin+Sulfonylurea+DPP-4/GLP-1   16 (21.9%)           33 (28.0%)         0.349
  Other                                19 (26.0%)           36 (30.5%)         0.445
  No data                              1 (1.4%)             9 (7.6%)           n/a

Error is expressed in 95% CIs. A '\*' label denotes a significant difference between groups.

As seen in [figure 2](#BMJDRC2015000134F2){ref-type="fig"}, the frequent tester group showed a statistically significant decrease in A1C from 7.9±0.4% (63±5 mmol/mol) to 7.4±0.2% (57±2 mmol/mol, p\<0.05) when comparing infrequent and frequent reporters. The infrequent testing group did not show a similar statistically significant decrease.

![Subgroup comparison of differences in average A1C when reporting more or less frequently, as grouped into (A) infrequent testers and (B) frequent testers.](bmjdrc2015000134f02){#BMJDRC2015000134F2}

Discussion {#s3}
==========

Testing two or more times a day, when combined with frequent reporting to a healthcare provider, was shown to be associated with a lower A1C in type 2 patients solely on oral medications. This finding supports the conclusion that a high degree of both patient and provider involvement in SMBG increases therapeutic effectiveness in this demographic.

The frequency of SMBG alone was not correlated to A1C, a finding consistent with previous investigations.[@R9] While frequent SMBG has been shown previously to correlate with a lower A1C in patients with type 1 diabetes, (15,16) this relationship was not observed in the non-insulin-dependent type 2 patients in this study. This difference may be reasonably explained by the fact that there is no ubiquitous response to blood sugar readings for patients that do not take insulin. Type 1 patients can be provided with very clear guidelines on adjusting their day-to-day insulin doses in response to their blood sugar readings, while type 2 patients often must juggle multiple oral medications along with diet and exercise. Without timely feedback from their healthcare provider, type 2 patients may not be equipped to make meaningful use of the information gained by testing their blood sugars at a high frequency.

As an established method for bridging the gap between clinic visits and ultimately reducing patient A1C,[@R17] a higher frequency of reporting using the Internet Blood Glucose Monitoring System (IBGMS) was shown to correlate with a lower A1C in non-insulin-dependent patients with type 2 diabetes. Interestingly, a positive correlation was found between SMBG frequency and reporting frequency, suggesting that highly compliant patients undergoing SMBG therapy may be strong candidates for the successful addition of IBGMS reporting. Further investigation into an interactive effect between SMBG and reporting suggests that only frequent testers may see the benefit of reporting their sugars. Only the subgroup of patients testing their blood sugars roughly two times a day or more showed a significant drop in A1C between infrequent and frequent reporters. No apparent benefit in reporting was observed in the more infrequent testing subgroup.

As a retrospective chart review, the causative effect of testing and reporting on A1C must be interpreted with caution. Just as testing and reporting may influence A1C, consideration must be given to the possibility that A1C itself may influence patient behaviors through associated frequency of adverse events, acute symptoms, or other reasons. As suggested by the significantly higher proportion of infrequent reporters on Metformin therapy, other factors such as intensity of treatment may also affect patient behaviors. The correlations determined via regression analyses, while statistically significant, have low R^2^ values, indicating a significant level of unexplained variance in the model. This is to be expected to some degree due to the fact that the test parameters are affected by behavior, something inherently difficult to account for in our statistical model. Despite these shortcomings, the conclusions of this study are in accordance with similar findings in a type 2 randomized control trial for insulin-dependent patients.[@R11] [@R12]

Owing to the limited scope of the study, certain features of the data set are important to note. The time frame for each individual\'s data was not controlled for, leading to differences in reporting consistency as well as potential differences between those recently enrolled in the program and those that have been reporting for a year or more. The therapeutic effect of IBGMS has been observed to dissipate after discontinuation on the program, however,[@R11] suggesting that there may be minimal long-term effects on patient behaviors at play. It is worth noting that the patient subgroupings were unequally distributed, thereby affecting the statistical power in the frequent tester group and resulting in less power in the infrequent group to detect differences. A more robust study, able to maintain statistical power while subdividing patients by diabetes history and treatment in a more balanced manner, would help to mitigate these factors. Despite this, as IBGMS is offered as a treatment option to all patients at this clinic, the patients sampled would ideally represent a generalized type 2 population of clinical significance.

This study demonstrates that only a combination of both frequent blood glucose self-monitoring and frequent communication with a healthcare provider may have an effect in lowering A1C in patients with type 2 diabetes solely on oral medications. As a contribution to the ongoing discussion of SMBG testing in non-insulin-dependent patients with diabetes, our data suggest that regular patient-provider interaction with actionable feedback, such as the IBGMS reporting model followed in this study, justifies SMBG in this patient group. We recommend the incorporation of IBGMS reporting into any new and previously established SMBG therapies.

The authors wish to pay our respects to Dr Hugh Tildesley for his lifetime passion for diabetes management and for his pioneering work in the field of internet blood glucose monitoring. He will be greatly missed by both his peers and patients. Portions of this study have been presented in abstract form at the International Diabetes Federation World Diabetes Congress, Vancouver, Canada, on December 2015.
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